World News: 13:30 GMT Thursday 30th May 2019. [Aeglea BioTherapeutics, Inc. via Globe Newswire via SPi World News]
AUSTIN, Texas, May 30, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that engineers next-generation human enzymes to provide solutions for diseases with unmet medical need, today announced that Anthony G. Quinn, M.B. Ch.B, Ph.D., president and chief executive officer of Aeglea, will participate in the following investor and industry conferences in June.
Globe Newswire: 13:30 GMT Thursday 30th May 2019
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.